EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis

María Ángeles González-Nicolás iD, Blanca Humanes, Raquel Herrero, Mario Arenillas iD, Beatriz López, Antonio Ferruelo, José Ángel Lorente iD, Alberto Lázaro iD

International Journal of Molecular Sciences · 16.08.2025 · 26 (16) · 7927

DOI: 10.3390/ijms26167927 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.08.2025. Verfasst von María Ángeles González-Nicolás und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gre…. Hauptthemen laut MEDLINE: Sepsis, Acute Kidney Injury, Cilastatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Ministry of Economy and Competitiveness Instituto de Salud Carlos III-Fondo de Investigación en Salud, Spanish Ministry of Economy and Competitiveness Instituto de Salud Carlos III-Fondo de Investigación en Salud, RICORS2040-Renal, Spanish Ministry of Science and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sepsis is a life-threatening condition caused by an abnormal host response to infection, leading to organ dysfunction and potentially death. Acute kidney injury (AKI) is a critical complication of sepsis. Various pathways, especially signaling through Toll-like receptors (TLRs) and the nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome, contribute to inflammation and tissue damage. Cilastatin, a renal dehydropeptidase I inhibitor, has shown promise in protecting against AKI induced by nephrotoxic drugs. This study assessed cilastatin’s effectiveness in preventing AKI and inflammation caused by sepsis and its impact on survival. Sepsis was induced in male Sprague-Dawley rats using the cecal ligation puncture (CLP) model, with four groups: sham (control), CLP, sham + cilastatin, and CLP + cilastatin. Cilastatin (150 mg/kg) was administered immediately and 24 h after sepsis induction. Kidney injury was evaluated 48 h later by assessing serum creatinine, blood urea nitrogen, glomerular filtration rate, proteinuria, kidney injury molecule-1 levels, and renal morphology. Inflammatory and fibrotic biomarkers, particularly related to the TLR4 and NLRP3 pathways, were also measured. Cilastatin treatment prevented kidney dysfunction, reduced inflammatory markers, and improved survival by 33%. These results suggest that cilastatin could be a beneficial therapeutic strategy for sepsis-related AKI, improving outcomes and reducing mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SepsisAcute Kidney InjuryCilastatinAnimalsMaleRatsRats, Sprague-DawleyDisease Models, AnimalNLR Family, Pyrin Domain-Containing 3 ProteinKidneyToll-Like Receptor 4Blood Urea NitrogenBiomarkersCreatinine

Stichwörter der Autor:innen

CLPTLR4acute kidney injurycilastatininflammationnephroprotectionsepsis

Substanzen

CilastatinNLR Family, Pyrin Domain-Containing 3 ProteinToll-Like Receptor 4BiomarkersCreatinineNlrp3 protein, rat

Autor:innen und Institutionen

  • Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
  • Department of Physiology, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain.
  • RICORS2040, 28007 Madrid, Spain.
  • Department of Critical Care Medicine, Hospital Universitario de Getafe, 28905 Madrid, Spain.
  • CIBER de Enfermedades Respiratorias, Instituto de Investigación Carlos III, 28029 Madrid, Spain.
  • Fundación de Investigación Biomédica del Hospital Universitario de Getafe, 28905 Madrid, Spain.

ORCID-Profile: María Ángeles González-Nicolás, Mario Arenillas, José Ángel Lorente, Alberto Lázaro

Förderung

  • Spanish Ministry of Economy and Competitiveness Instituto de Salud Carlos III-Fondo de Investigación en Salud
  • Spanish Ministry of Economy and Competitiveness Instituto de Salud Carlos III-Fondo de Investigación en Salud, RICORS2040-Renal
  • Spanish Ministry of Science and Innovation
  • Comunidad de Madrid
  • Fundación Mutua Madrileña

Zitieren

APA

González-Nicolás, M. Á., Humanes, B., Herrero, R., Arenillas, M., López, B., Ferruelo, A., Lorente, J. Á., & Lázaro, A. (2025). Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis. International Journal of Molecular Sciences, 26(16), 7927. https://doi.org/10.3390/ijms26167927

Vancouver

González-Nicolás MÁ, Humanes B, Herrero R, Arenillas M, López B, Ferruelo A, et al. Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis. International Journal of Molecular Sciences. 2025;26(16):7927. doi:10.3390/ijms26167927

BibTeX
@article{GonzlezNicols2025,
  author = {González-Nicolás, María Ángeles and Humanes, Blanca and Herrero, Raquel and Arenillas, Mario and López, Beatriz and Ferruelo, Antonio and Lorente, José Ángel and Lázaro, Alberto},
  title = {Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {16},
  pages = {7927},
  doi = {10.3390/ijms26167927}
}
Kostenlos starten →